VIR News and Press, Vir Biotechnology Inc. From 01/13/22

– If authorized, would provide the option for intramuscular administration of sotrovimab, in addition to currently authorized intravenous administration – –  Submission follows COMET-TAIL Phase 3 data demonstrating that intramuscular administration...

– 600,000 additional doses to be supplied to the US government for distribution in Q1 2022, enabling further access to sotrovimab nationwide – – Brings total number of doses secured to date through binding agreements to approximately 1.7 mi...

It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive. Pfizer ...

SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will present at the 40 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, at 1:30 p.m. ET. The conference wi...

–  Growing body of evidence validates Vir’s approach of targeting a highly conserved region of the spike protein – – Together with recent pseudo- and live virus results, additional preclinical data reinforce sotrovimab retains in vitro neutr...

BiondVax Pharmaceuticals (NASDAQ:BVXV) +55% signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center Göttingen, Germany. BioRestorative Therapi...

Deal-making exerted influence in Tuesday's midday action. Citrix Systems (NASDAQ:CTXS) gained ground on reports of a potential takeover offer. At the same time, Embraer (NYSE:ERJ) received buying interest after it announced a SPAC deal to take its electric aircraft unit public. In other news,...

Gainers: Reliance Global Group (NASDAQ:RELI) +82%. Biofrontera (NASDAQ:BFRI) +49%. Jaguar Health (NASDAQ:JAGX) +43%. IsoPlexis (NASDAQ:ISO) +31%. Aridis Pharmaceuticals (NASDAQ:ARDS) +28%. Petros Pharmaceuticals (NASDAQ:PTPI) +30%. Eqonex (NASDAQ:EQOS) +26%. Quantum-Si incorporated (NASDAQ:QS...

Baird analyst Joel Beatty downgraded Vir Biotechnology (NASDAQ:VIR) to Underperform from Neutral with a price target of $36. VIR shares down 2.3% premarket to $50. The stock has gained around 56% since late November following the first reports of Omicron variant. However, Betty beli...

Can-Fite BioPharma (NYSE:CANF) +71% liver cancer patient treated with can-Fite’s Namodenoson clears all cancer lesions under open label extension of phase II study. Society Pass Incorporated (NASDAQ:SOPA) +35% on being added to the Russell 2000 Index. Verso (NYSE:VRS) +3...